GCGR and type 2 diabetes mellitus: These studies are typical of others that have led to development of peptidergic glucagon receptor antagonists for T2DM, in particular the first reported antagonistic, glucagon analogue [l-N alphatrinitrophenylhistidine, 12-homoarginine]-glucagon, which elicited decreases in circulating glucose of up to 65% with continuous infusion in anaesthetised rats (356).